|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CNIH4 |
Gene summary for CNIH4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CNIH4 | Gene ID | 29097 |
| Gene name | cornichon family AMPA receptor auxiliary protein 4 | |
| Gene Alias | CNIH-4 | |
| Cytomap | 1q42.11 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9P003 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 29097 | CNIH4 | LZE2T | Human | Esophagus | ESCC | 1.84e-09 | 2.03e+00 | 0.082 |
| 29097 | CNIH4 | LZE4T | Human | Esophagus | ESCC | 8.12e-24 | 9.67e-01 | 0.0811 |
| 29097 | CNIH4 | LZE5T | Human | Esophagus | ESCC | 2.75e-05 | 6.62e-01 | 0.0514 |
| 29097 | CNIH4 | LZE7T | Human | Esophagus | ESCC | 2.61e-10 | 1.10e+00 | 0.0667 |
| 29097 | CNIH4 | LZE8T | Human | Esophagus | ESCC | 5.06e-09 | 3.95e-01 | 0.067 |
| 29097 | CNIH4 | LZE20T | Human | Esophagus | ESCC | 1.14e-07 | 4.89e-01 | 0.0662 |
| 29097 | CNIH4 | LZE22D1 | Human | Esophagus | HGIN | 6.74e-03 | 5.65e-02 | 0.0595 |
| 29097 | CNIH4 | LZE22T | Human | Esophagus | ESCC | 2.30e-04 | 9.48e-01 | 0.068 |
| 29097 | CNIH4 | LZE24T | Human | Esophagus | ESCC | 5.65e-20 | 8.88e-01 | 0.0596 |
| 29097 | CNIH4 | LZE6T | Human | Esophagus | ESCC | 3.21e-14 | 1.26e+00 | 0.0845 |
| 29097 | CNIH4 | P1T-E | Human | Esophagus | ESCC | 7.00e-09 | 1.02e+00 | 0.0875 |
| 29097 | CNIH4 | P2T-E | Human | Esophagus | ESCC | 8.88e-54 | 1.22e+00 | 0.1177 |
| 29097 | CNIH4 | P4T-E | Human | Esophagus | ESCC | 8.34e-48 | 1.26e+00 | 0.1323 |
| 29097 | CNIH4 | P5T-E | Human | Esophagus | ESCC | 5.79e-92 | 2.02e+00 | 0.1327 |
| 29097 | CNIH4 | P8T-E | Human | Esophagus | ESCC | 4.58e-31 | 7.92e-01 | 0.0889 |
| 29097 | CNIH4 | P9T-E | Human | Esophagus | ESCC | 2.18e-45 | 1.38e+00 | 0.1131 |
| 29097 | CNIH4 | P10T-E | Human | Esophagus | ESCC | 2.92e-52 | 1.17e+00 | 0.116 |
| 29097 | CNIH4 | P11T-E | Human | Esophagus | ESCC | 4.41e-19 | 1.30e+00 | 0.1426 |
| 29097 | CNIH4 | P12T-E | Human | Esophagus | ESCC | 6.93e-51 | 9.61e-01 | 0.1122 |
| 29097 | CNIH4 | P15T-E | Human | Esophagus | ESCC | 6.15e-44 | 1.23e+00 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004819317 | Esophagus | HGIN | Golgi vesicle transport | 83/2587 | 296/18723 | 8.59e-11 | 8.89e-09 | 83 |
| GO:00068889 | Esophagus | HGIN | endoplasmic reticulum to Golgi vesicle-mediated transport | 40/2587 | 130/18723 | 4.67e-07 | 2.07e-05 | 40 |
| GO:004819318 | Esophagus | ESCC | Golgi vesicle transport | 231/8552 | 296/18723 | 1.82e-30 | 9.63e-28 | 231 |
| GO:000688815 | Esophagus | ESCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 102/8552 | 130/18723 | 1.73e-14 | 9.22e-13 | 102 |
| GO:004819311 | Liver | Cirrhotic | Golgi vesicle transport | 153/4634 | 296/18723 | 1.02e-23 | 6.43e-21 | 153 |
| GO:000688811 | Liver | Cirrhotic | endoplasmic reticulum to Golgi vesicle-mediated transport | 77/4634 | 130/18723 | 5.78e-17 | 7.56e-15 | 77 |
| GO:004819321 | Liver | HCC | Golgi vesicle transport | 217/7958 | 296/18723 | 2.58e-27 | 1.02e-24 | 217 |
| GO:000688821 | Liver | HCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 100/7958 | 130/18723 | 1.15e-15 | 8.67e-14 | 100 |
| GO:004819315 | Oral cavity | OSCC | Golgi vesicle transport | 209/7305 | 296/18723 | 1.39e-28 | 6.30e-26 | 209 |
| GO:00068888 | Oral cavity | OSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 97/7305 | 130/18723 | 1.42e-16 | 1.15e-14 | 97 |
| GO:004819316 | Oral cavity | LP | Golgi vesicle transport | 141/4623 | 296/18723 | 6.11e-18 | 1.06e-15 | 141 |
| GO:000688814 | Oral cavity | LP | endoplasmic reticulum to Golgi vesicle-mediated transport | 67/4623 | 130/18723 | 3.74e-11 | 2.39e-09 | 67 |
| GO:004819310 | Prostate | BPH | Golgi vesicle transport | 102/3107 | 296/18723 | 3.90e-14 | 4.56e-12 | 102 |
| GO:00068887 | Prostate | BPH | endoplasmic reticulum to Golgi vesicle-mediated transport | 46/3107 | 130/18723 | 1.53e-07 | 3.53e-06 | 46 |
| GO:004819314 | Prostate | Tumor | Golgi vesicle transport | 105/3246 | 296/18723 | 3.55e-14 | 4.33e-12 | 105 |
| GO:000688813 | Prostate | Tumor | endoplasmic reticulum to Golgi vesicle-mediated transport | 49/3246 | 130/18723 | 2.49e-08 | 8.33e-07 | 49 |
| GO:0048193110 | Skin | cSCC | Golgi vesicle transport | 153/4864 | 296/18723 | 1.85e-21 | 3.41e-19 | 153 |
| GO:000688810 | Skin | cSCC | endoplasmic reticulum to Golgi vesicle-mediated transport | 73/4864 | 130/18723 | 2.60e-13 | 1.57e-11 | 73 |
| GO:004819320 | Thyroid | PTC | Golgi vesicle transport | 186/5968 | 296/18723 | 3.09e-28 | 1.22e-25 | 186 |
| GO:000688817 | Thyroid | PTC | endoplasmic reticulum to Golgi vesicle-mediated transport | 83/5968 | 130/18723 | 6.19e-14 | 3.52e-12 | 83 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CNIH4 | SNV | Missense_Mutation | novel | c.279G>T | p.Met93Ile | p.M93I | Q9P003 | protein_coding | tolerated(0.36) | benign(0.025) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| CNIH4 | SNV | Missense_Mutation | c.125N>T | p.Ser42Leu | p.S42L | Q9P003 | protein_coding | deleterious(0.02) | benign(0.3) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CNIH4 | SNV | Missense_Mutation | c.408N>C | p.Leu136Phe | p.L136F | Q9P003 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| CNIH4 | SNV | Missense_Mutation | novel | c.371N>A | p.Cys124Tyr | p.C124Y | Q9P003 | protein_coding | tolerated(1) | benign(0.272) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CNIH4 | insertion | Frame_Shift_Ins | novel | c.392_392+1insTATGATCTTAGCTTTGATAAATGACT | p.Ter140LeufsTer2 | p.*140Lfs*2 | Q9P003 | protein_coding | TCGA-66-2793-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | ||
| CNIH4 | SNV | Missense_Mutation | novel | c.69N>G | p.Phe23Leu | p.F23L | Q9P003 | protein_coding | deleterious(0.01) | benign(0.007) | TCGA-CV-A45Q-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CNIH4 | SNV | Missense_Mutation | novel | c.325N>C | p.Ser109Pro | p.S109P | Q9P003 | protein_coding | tolerated(0.23) | possibly_damaging(0.761) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |